Stock listing
NASDAQ:ACIU AC Immune SA Stock
Home listing (NASDAQ) of AC Immune SA
Follow AC Immune SA into a list and get an email when it puts out news.
Share price · NASDAQ:ACIU
$1.95 USD -0.15 (-7.1%)
Close on Nov 20, 2026
- Day range
- $1.93 – $2.16 USDNov 20, 2026
- Volume
- 298,383 sharesNov 20, 2026
- Market cap
- $193.9M USDAt the close on Nov 20, 2026 · price × 99.43M shares outstanding
- 52-week range
- $1.93 – $3.90 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $497,312 USDMedian day 148,474 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACIU · Home | $1.95 USD | -0.15 (-7.1%) | 298,383 | $2.16 | $2.16 | $1.93 | $2.10 | Close on Nov 20, 2026 |
| Frankfurt:IMR | €1.82 EUR | +0.04 (+2.2%) | — | €1.856 | €1.856 | €1.82 | €1.78 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACIU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.95 | -0.15 | -7.1% | $2.16 | $2.16 | $1.93 | 298,383 | |
| $2.10 | -0.01 | -0.5% | $2.16 | $2.16 | $2.076 | 80,189 | |
| $2.11 | +0.02 | +1.0% | $2.06 | $2.13 | $2.031 | 117,134 | |
| $2.09 | -0.04 | -1.9% | $2.08 | $2.11 | $2.04 | 99,323 | |
| $2.13 | -0.01 | -0.5% | $2.21 | $2.21 | $2.075 | 114,784 | |
| $2.14 | -0.12 | -5.3% | $2.21 | $2.23 | $2.12 | 121,753 | |
| $2.26 | -0.03 | -1.3% | $2.32 | $2.33 | $2.23 | 91,386 | |
| $2.29 | -0.15 | -6.1% | $2.38 | $2.39 | $2.28 | 144,157 | |
| $2.44 | +0.21 | +9.4% | $2.32 | $2.55 | $2.17 | 469,484 | |
| $2.23 | +0.12 | +5.7% | $2.10 | $2.25 | $2.095 | 180,406 | |
| $2.11 | -0.18 | -7.9% | $2.26 | $2.26 | $2.02 | 301,977 | |
| $2.29 | +0.20 | +9.6% | $2.18 | $2.29 | $2.13 | 324,624 | |
| $2.09 | +0.03 | +1.5% | $2.06 | $2.16 | $2.06 | 134,320 | |
| $2.06 | -0.16 | -7.2% | $2.23 | $2.32 | $2.015 | 470,827 | |
| $2.22 | -0.15 | -6.3% | $2.37 | $2.37 | $2.21 | 105,104 | |
| $2.37 | 0.00 | 0.0% | $2.34 | $2.43 | $2.32 | 105,208 | |
| $2.37 | +0.12 | +5.3% | $2.21 | $2.39 | $2.19 | 227,120 | |
| $2.25 | -0.06 | -2.6% | $2.31 | $2.36 | $2.03 | 469,024 | |
| $2.31 | -0.11 | -4.5% | $2.41 | $2.42 | $2.29 | 397,919 | |
| $2.42 | -0.08 | -3.2% | $2.46 | $2.48 | $2.40 | 139,548 | |
| $2.50 | +0.03 | +1.2% | $2.45 | $2.52 | $2.45 | 73,027 | |
| $2.47 | -0.02 | -0.8% | $2.46 | $2.52 | $2.46 | 89,033 | |
| $2.49 | +0.055 | +2.3% | $2.41 | $2.525 | $2.395 | 140,103 | |
| $2.435 | +0.045 | +1.9% | $2.38 | $2.44 | $2.37 | 88,823 | |
| $2.39 | -0.06 | -2.4% | $2.45 | $2.47 | $2.38 | 126,849 | |
| $2.45 | +0.05 | +2.1% | $2.43 | $2.46 | $2.381 | 86,886 | |
| $2.40 | 0.00 | 0.0% | $2.37 | $2.41 | $2.35 | 209,775 | |
| $2.40 | -0.05 | -2.0% | $2.43 | $2.44 | $2.39 | 194,919 | |
| $2.45 | -0.05 | -2.0% | $2.50 | $2.50 | $2.42 | 148,474 | |
| $2.50 | -0.05 | -2.0% | $2.55 | $2.59 | $2.475 | 271,325 | |
| $2.55 | -0.02 | -0.8% | $2.57 | $2.61 | $2.50 | 231,857 | |
| $2.57 | +0.05 | +2.0% | $2.52 | $2.59 | $2.50 | 125,080 | |
| $2.52 | -0.19 | -7.0% | $2.72 | $2.72 | $2.51 | 277,841 | |
| $2.71 | -0.015 | -0.6% | $2.68 | $2.745 | $2.65 | 221,399 | |
| $2.725 | -0.085 | -3.0% | $2.84 | $2.88 | $2.69 | 320,257 | |
| $2.81 | +0.19 | +7.3% | $2.64 | $2.835 | $2.57 | 352,697 | |
| $2.62 | +0.02 | +0.8% | $2.63 | $2.745 | $2.61 | 199,646 | |
| $2.60 | -0.01 | -0.4% | $2.65 | $2.66 | $2.56 | 139,228 | |
| $2.61 | +0.09 | +3.6% | $2.52 | $2.62 | $2.405 | 189,115 | |
| $2.52 | -0.14 | -5.3% | $2.66 | $2.66 | $2.452 | 323,580 | |
| $2.66 | -0.17 | -6.0% | $2.85 | $2.85 | $2.66 | 265,287 | |
| $2.83 | +0.10 | +3.7% | $2.90 | $2.907 | $2.669 | 492,823 | |
| $2.73 | +0.075 | +2.8% | $2.69 | $2.75 | $2.66 | 78,091 | |
| $2.655 | +0.025 | +1.0% | $2.63 | $2.72 | $2.57 | 109,425 | |
| $2.63 | -0.05 | -1.9% | $2.69 | $2.806 | $2.625 | 68,461 | |
| $2.68 | +0.03 | +1.1% | $2.71 | $2.74 | $2.66 | 93,347 | |
| $2.65 | -0.03 | -1.1% | $2.68 | $2.73 | $2.61 | 124,399 | |
| $2.68 | +0.02 | +0.8% | $2.65 | $2.70 | $2.59 | 93,530 | |
| $2.66 | -0.10 | -3.6% | $2.69 | $2.75 | $2.66 | 111,832 | |
| $2.76 | +0.07 | +2.6% | $2.70 | $2.775 | $2.68 | 105,369 | |
| $2.69 | -0.07 | -2.5% | $2.74 | $2.77 | $2.68 | 157,532 | |
| $2.76 | -0.02 | -0.7% | $2.78 | $2.81 | $2.725 | 146,572 | |
| $2.78 | -0.08 | -2.8% | $2.82 | $2.85 | $2.77 | 100,865 | |
| $2.86 | -0.07 | -2.4% | $2.91 | $2.94 | $2.82 | 155,628 | |
| $2.93 | +0.09 | +3.2% | $2.85 | $3.00 | $2.85 | 171,765 | |
| $2.84 | +0.16 | +6.0% | $2.70 | $2.865 | $2.70 | 257,176 | |
| $2.68 | +0.04 | +1.5% | $2.62 | $2.68 | $2.58 | 103,465 | |
| $2.64 | -0.01 | -0.4% | $2.67 | $2.735 | $2.61 | 132,959 | |
| $2.65 | -0.06 | -2.2% | $2.73 | $2.77 | $2.65 | 105,711 | |
| $2.71 | -0.14 | -4.9% | $2.83 | $2.91 | $2.685 | 169,433 | |
| $2.85 | -0.07 | -2.4% | $2.94 | $2.98 | $2.77 | 269,061 | |
| $2.92 | +0.06 | +2.1% | $2.85 | $2.965 | $2.85 | 241,303 | |
| $2.86 | -0.04 | -1.4% | $2.91 | $3.00 | $2.799 | 371,172 | |
| $2.90 | +0.26 | +9.8% | $2.66 | $2.945 | $2.65 | 442,012 | |
| $2.64 | +0.06 | +2.3% | $2.60 | $2.65 | $2.435 | 237,111 |
- Ticker
- NASDAQ:ACIU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
AC Immune to Present at Jefferies Global Healthcare Conference 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 18 slides
Latest news
AC Immune to Present at Jefferies Global Healthcare Conference 2026
Nov 11, 2026
Closed $2.26 (-1.3%) on Nov 11, 2026
AC Immune Third Quarter 2026 Financial and Corporate Update
Nov 4, 2026
Closed $2.29 (+9.6%) on Nov 4, 2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Aug 11, 2026
Closed $2.54 (+11.4%) on Aug 11, 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Jul 7, 2026
Closed $2.54 (+1.2%) on Jul 7, 2026
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Jun 30, 2026
Closed $2.38 (-10.5%) on Jun 30, 2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Jun 11, 2026
Closed $2.26 (+6.6%) on Jun 11, 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026
Closed $2.83 (-0.7%) on May 22, 2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
May 12, 2026
Closed $2.77 (-2.1%) on May 12, 2026
AC Immune First Quarter 2026 Financial and Corporate Updates
Apr 30, 2026
Closed $3.03 (+3.4%) on Apr 30, 2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Apr 30, 2026
Closed $3.03 (+3.4%) on Apr 30, 2026
AC Immune SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 124 in all · newest Nov 11, 2026 · oldest 2019
- Decks
- 27 decks · latest October 2026
Where AC Immune SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACIU · Home listing · This page | NASDAQ | United States | USD |
| gettex:IMR | gettex | Germany | EUR |
| LS Exchange:A2AR5F | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AR5F | Lang & Schwarz | Germany | EUR |
| Frankfurt:IMR | Frankfurt | Germany | EUR |
| BOATS:ACIU | BOATS | United States | USD |
| Tradegate:IMR | Tradegate | Germany | EUR |
| Dusseldorf:IMR | Dusseldorf | Germany | EUR |
| Hamburg:IMR | Hamburg | Germany | EUR |
| Munich:IMR | Munich | Germany | EUR |
| Stuttgart:IMR | Stuttgart | Germany | EUR |
| Hanover:IMR | Hanover | Germany | EUR |
| Xetra:IMR | Xetra | Germany | EUR |
Valuation
EV/sales 4.7× against a median of 14.0×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $110.5M USD
- P/E
- Loss
- EV/sales
- 4.7×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.0×
- Gross margin
- 100.0%
- Operating margin
- −190.8%
- Net margin
- −181.9%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| Cabaletta Bio, Inc. · NASDAQ:CABA | US$201.9M | −US$97.45M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.89 |
| Bright Minds Biosciences Inc. · CSE:DRUG | US$199.5M | −US$15.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.32 |
| Newron Pharmaceuticals S.p.A. · SIX:NWRN | US$199.5M | US$206.2M | n/a | 9.8× | n/a | n/a | −69.2% | n/a | n/a |
| NervGen Pharma Corp. · NASDAQ:NGEN | US$198.4M | US$137.8M | n/a | n/a | n/a | 16.4× | n/a | 0.0× | 1.46 |
| BioAge Labs, Inc. · NASDAQ:BIOA | US$196.4M | −US$87.20M | n/a | −10.1× | n/a | 0.6× | n/a | 0.0× | 2.06 |
| Lineage Cell Therapeutics, Inc. · AMEX:LCTX | US$195.3M | US$152.1M | 111× | 14.0× | n/a | 2.9× | 16.2% | 0.0× | 1.33 |
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| SillaJen, Inc. · KRX:215600 | US$192.3M | US$140.8M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Median of the others | US$195.8M | US$121.4M | 111× | 14.0× | 1.7× | −69.2% | 0.0× | 1.34 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.34 · 2 analysts
- Revenue, year to Dec 2026
- 22M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gary Waanders | SVP, Investor Relations & Corporate Communications |
Board
| Director | Role |
|---|---|
| Monika Bütler | Chairperson |
| Renée Aguiar-Lucander | Member |
| Roy Twyman | Member |
| Thomas Graney | Member |
Events
- Next results
- Mar 11, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +9.6% |
| Q2 2026 | Aug 5, 2026 · Before open | +0.9% |
| Q1 2026 | Apr 30, 2026 · Before open | +3.4% |
| Q4 2025 | Mar 12, 2026 | −1.5% |
| Q3 2025 | Nov 4, 2025 · Before open | +3.8% |
| Q2 2025 | Aug 5, 2025 · Before open | +11.6% |
| Q1 2025 | Apr 30, 2025 · Before open | +1.8% |
| Q4 2024 | Mar 12, 2025 · Before open | +3.1% |
| Q3 2024 | Nov 5, 2024 · Before open | +10.2% |
| Q2 2024 | Aug 6, 2024 · Before open | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +42.9% |
| Q4 2023 | Mar 14, 2024 · Before open | −10.0% |
| Q3 2023 | Nov 3, 2023 · Before open | −3.9% |
| Q2 2023 | Aug 4, 2023 · Before open | +3.1% |
| Q1 2023 | Apr 28, 2023 · Before open | +3.2% |
| Q4 2022 | Mar 16, 2023 · Before open | +0.4% |
| Q3 2022 | Oct 28, 2022 · Before open | −6.6% |
| Q2 2022 | Jul 28, 2022 · Before open | +4.4% |
| Q1 2022 | Apr 28, 2022 · Before open | −0.9% |
| Q4 2021 | Mar 22, 2022 · Before open | −0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 18 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Shareholder Meeting (June 2026) | Shareholder meeting | 43 slides | Jun 11, 2026 |
| Shareholder Meeting (June 2025) | Shareholder meeting | 47 slides | Jun 20, 2025 |
| Shareholder Meeting (June 2024) | Shareholder meeting | 39 slides | Jun 20, 2024 |
| Investor Presentation (May 2024) | Investor deck | 11 slides | May 2024 |
| AD/PD 2024 | Conference | 12 slides | Mar 9, 2024 |
| AD/PD 2024 | Conference | 13 slides | Mar 6, 2024 |
| ADPD 2024 | Conference | 11 slides | March 2024 |
| AAIC 2023 | Conference | 16 slides | Jul 18, 2023 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (June 2023) | Shareholder meeting | 49 slides | Jun 26, 2023 |
| AAIC 2022 | Conference | 13 slides | Aug 2, 2022 |
| Shareholder Meeting (June 2022) | Shareholder meeting | 50 slides | Jun 24, 2022 |
| AD/PD 2022 | Conference | 12 slides | Mar 18, 2022 |
| CTAD 2021 (Clinical Trials on Alzheimer's Disease), Boston | Conference | 15 slides | November 2021 |
| Shareholder Meeting (June 2021) | Shareholder meeting | 37 slides | Jun 25, 2021 |
| Shareholder Meeting (June 2020) | Shareholder meeting | 34 slides | Jun 26, 2020 |
| Investor Presentation (November 2019) | Investor deck | 26 slides | Nov 6, 2019 |
| Technical Presentation (November 2019) | Technical | 32 slides | Nov 6, 2019 |
| KOL Breakfast NYC July 2019 | Conference | 25 slides | Jul 11, 2019 |
| Shareholder Meeting (June 2019) | Shareholder meeting | 53 slides | Jun 28, 2019 |
| CTAD 2018 late breaking session | Conference | 18 slides | Oct 26, 2018 |
| Shareholder Meeting (July 2018) | Shareholder meeting | 53 slides | Jul 6, 2018 |
| Shareholder Meeting (April 2018) | Shareholder meeting | 26 slides | Apr 27, 2018 |
| Shareholder Meeting (June 2017) | Shareholder meeting | 47 slides | Jun 28, 2017 |
| Technical Presentation (December 2016) | Technical | 10 slides | Dec 16, 2016 |
| Shareholder Meeting (November 2016) | Shareholder meeting | 16 slides | Nov 15, 2016 |
IPO
Priced at US$11.00 a share on Sep 22, 2016.
- Price
- US$11.00 a share
- Shares offered
- 6,000,000 common shares
- Offering size
- US$66 million
- Underwriters' option
- Up to 900,000 more shares
- Underwriters
- Credit Suisse, Jefferies, Leerink Partners · In the order on the cover
- Shares delivered
- On or about Sep 28, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 28, 2015 |
| Filed publicly | May 31, 2016 |
| Amended 7 times | Newest Sep 22, 2016 |
| Declared effective by the SEC | Sep 22, 2016 |
| Shares registered with an exchange | Sep 23, 2016 |
| Final prospectus, with the price | Sep 23, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 23, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Sep 23, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 23, 2016 |
| EFFECT · Notice that a registration is effective | Sep 22, 2016 |
| F-1/A · Registration statement, amended | Sep 22, 2016 |
| FWP · Free writing prospectus | Sep 21, 2016 |
| F-1/A · Registration statement, amended | Sep 21, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
All 40 filings
Open IPO · From the cover of the final prospectus (424B4) filed Sep 23, 2016
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57M | 27.3M | 14.8M | 3.94M | 0 | 15.4M | 110.5M | 6.91M | 20.3M | 23.2M |
| Cost of revenue | 62.6M | 54.6M | 60.3M | 62.3M | 59.5M | 50.4M | 44.3M | 32.7M | 25.8M | |
| Gross profit | 3.57M | -35.3M | -39.8M | 3.94M | -62.3M | -44.1M | 60.0M | -37.1M | -12.4M | -2.56M |
| Research and development | 56.4M | 62.6M | 54.6M | 60.3M | 62.3M | 59.5M | 50.4M | 44.3M | 32.7M | 25.8M |
| Selling, general and administrative | 11.7M | 11.4M | 10.6M | 9.58M | 17.9M | 18.6M | 16.1M | 12.5M | 10.1M | 7.90M |
| Operating income | -69.3M | -52.4M | -53.6M | -70.8M | -79.0M | -61.3M | 44.5M | -49.5M | -22.5M | -10.5M |
| Depreciation and amortization | 1.39M | 1.49M | 1.67M | 1.79M | 1.90M | 1.53M | 1.27M | 961.0K | 580.0K | 278.0K |
| EBITDA | -67.9M | -50.9M | -52.0M | -69.1M | -77.1M | -59.7M | 45.8M | -48.6M | -22.0M | -10.2M |
| Interest expense | 191.0K | 133.0K | 176.0K | 355.0K | 581.0K | 184.0K | 1.89M | 298.0K | 147.0K | 7.00K |
| Income before tax | -70.4M | -50.9M | -54.2M | -70.7M | -73.0M | -61.9M | 45.4M | -51.0M | -26.4M | -7.10M |
| Income tax | 0 | 3.00K | 10.0K | 13.0K | 3.00K | 0 | 0 | 0 | 0 | 0 |
| Net income | -70.4M | -50.9M | -54.2M | -70.8M | -73.0M | -61.9M | 45.4M | -51.0M | -26.4M | -7.10M |
| Earnings per share, basic | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 |
| Earnings per share, diluted | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.8M | 36.3M | 78.5M | 31.6M | 82.2M | 160.9M | 193.6M | 156.5M | 124.4M | 152.2M |
| Short-term investments | 64.7M | 129.2M | 24.6M | 91.0M | 116.0M | 65.0M | 95.0M | 30.0M | 0 | 0 |
| Receivables | 1.34M | 0 | 14.8M | 408.0K | 975.0K | 1.59M | 1.40M | 4.10M | 3.72M | 1.41M |
| Inventory | -622.0K | 1 | -1.40M | -1.92M | -1.40M | 0 | -1.36M | 389.0K | ||
| Current assets | 96.7M | 172.0M | 125.2M | 128.1M | 202.6M | 231.8M | 292.8M | 192.9M | 129.5M | 154.9M |
| Property, plant and equipment | 1.99M | 2.65M | 3.38M | 4.26M | 5.12M | 4.42M | 3.92M | 3.32M | 2.35M | 1.12M |
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 154.3M | 230.9M | 182.8M | 185.9M | 261.4M | 238.7M | 299.3M | 196.6M | 132.0M | 156.1M |
| Accounts payable | 2.07M | 2.66M | 1.68M | 929.0K | 2.00M | 2.18M | 142.0K | 1.98M | 1.09M | 4.04M |
| Current liabilities | 94.7M | 100.8M | 13.6M | 11.5M | 20.0M | 14.0M | 17.5M | 13.1M | 9.75M | 9.92M |
| Long-term debt | 0 | 186.0K | 395.0K | 0 | ||||||
| Total debt | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M | 2.22M | 2.91M | 551.8K | 498.4K | 0 |
| Total liabilities | 109.4M | 118.6M | 22.2M | 16.9M | 29.5M | 23.3M | 26.8M | 18.9M | 15.2M | 13.7M |
| Shareholders' equity | 44.9M | 112.3M | 160.6M | 169.0M | 232.0M | 215.5M | 272.4M | 177.6M | 116.8M | 142.4M |
| Shares outstanding | 100.8M | 99.7M | 84.7M | 83.6M | 75.0M | 71.9M | 71.1M | 61.8M | 57.4M | 50.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -69.3M | 65.8M | -60.4M | -73.6M | -65.7M | -59.5M | 55.2M | -44.1M | -22.1M | -5.65M |
| Capital spending | -900.0K | -576.0K | -801.0K | -1.24M | -2.63M | -1.71M | -1.89M | -1.86M | -1.80M | -899.0K |
| Free cash flow | -70.2M | 65.3M | -61.2M | -74.8M | -68.3M | -61.2M | 53.3M | -45.9M | -23.9M | -6.54M |
| Cash from investing | 63.5M | -105.3M | 65.6M | 23.8M | -53.7M | 28.3M | -66.9M | -32.0M | -1.84M | -899.0K |
| Cash from financing | -1.02M | -1.12M | 43.3M | -1.35M | 40.7M | -803.0K | 49.6M | 109.4M | 271.0K | 78.8M |
| Dividends paid | -7.00K | 0 | 0 | 0 | 0 | |||||
| Share buybacks | 0 | 0 | -100.0K | 0 | 0 | 71.0K | 82.9M | |||
| Change in cash | -6.74M | -40.6M | 48.5M | -51.2M | -78.6M | -32.0M | 38.0M | 33.3M | -23.7M | 72.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Oct 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 23, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 313 filings. Open Filings
Cap table
Built by 6ix from AC Immune SA’s releases
- Common shares
- 99,426,932
- Fully diluted
- 99,426,932
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 99,426,932 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 99,426,932 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Renée Aguiar-Lucander Other companies: Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past) | Member · Since at least Mar 18, 2026 |
| Andrea Pfeifer | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Carl Howard June | Director · Since at least Mar 18, 2026 |
| Christopher James Roberts | Chief Financial Officer · Since at least Mar 18, 2026 |
| Gary Waanders | SVP, Investor Relations & Corporate Communications · Since at least Nov 4, 2026 |
| Martin Zuegel | Interim CEO, Director · Since at least Mar 18, 2026 |
| Monika Buetler | Director · Since at least Jun 11, 2026 |
| Monika Bütler | Chairperson · Since at least Nov 5, 2026 |
| Piergiorgio Donati | Chief Operating Officer · Since at least Mar 20, 2026 |
| Roy Twyman | Member · Since at least Mar 18, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Thomas Graney | Member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AC Immune SA.